Breast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.

The Journal of Clinical Urology, published by SAGE Publications Ltd, is a prominent academic platform dedicated to advancing the field of urology and surgical medicine. With an ISSN of 2051-4158 and an E-ISSN of 2051-4166, this journal has been pivotal in disseminating cutting-edge research since its inception in 2008 and is set to continue through 2024. Although categorized in the Q4 quartile for both Surgery and Urology, and positioned in the 24th and 22nd percentiles respectively according to Scopus rankings, the journal remains an essential resource for professionals, researchers, and students who seek to understand clinical developments and innovative practices in urological surgery. While the journal does not operate under an Open Access model, it provides critical insights and valuable findings that significantly impact healthcare practices and patient outcomes in the urology field.

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.